For patients who experience frequent, prolonged, or debilitating migraine attacks, acute treatments alone are often insufficient. Unchecked attack frequency increases the risk of functional disability and medication overuse headache. Preventive therapy aims to reduce attack frequency, severity, and duration while improving acute treatment responsiveness and daily function. This article reviews evidence-based prophylactic pharmacotherapies, lifestyle strategies, and non-pharmacological modalities.
Indications for Preventive Therapy
Prophylactic therapy should be considered when a patient meets any of the following clinical criteria:
Recurring attacks that significantly disrupt daily activities despite acute treatment.
High headache frequency ($>4\text{ headache days per month}$).
Acute therapies are contraindicated, ineffective, poorly tolerated, or overused.
Presence of rare or disabling migraine variants (e.g., hemiplegic migraine, brainstem aura/basilar migraine).
Presence of unusually prolonged or uncomfortable aura.
General Principles of Prophylactic Pharmacotherapy
Start Low, Go Slow: Initiate treatment at a low dose and gradually titrate upward until clinical benefit is achieved, side effects limit further increases, or the maximum target dose is reached.
Ensure an Adequate Trial: A full preventive trial requires 2 to 6 months to evaluate maximum benefit, though initial improvement is often noted at 4 weeks.
Account for Comorbidities: Select agents that address co-existing conditions (e.g., choose a beta-blocker for hypertension or a TCA for comorbid depression/insomnia).
Monitor with a Headache Diary: Use a structured diary to track attack frequency, severity, and drug efficacy. If control is sustained for 3 to 6 months, gradual tapering may be attempted.
Evidence-Based Prophylactic Pharmacotherapies
American Academy of Neurology (AAN) and American Headache Society (AHS) guidelines categorize prophylactic medications by evidence level:
Level A Recommendations (Established Efficacy)
Antiepileptic Drugs (AEDs):
Divalproex Sodium / Sodium Valproate: Increases GABAergic neurotransmission and reduces excitatory amino acids, suppressing neurogenic inflammation. Dosing: Start at $250\text{ mg}$ at bedtime; titrate to $500\text{--}750\text{ mg/day}$. Monitoring: Obtain baseline liver function tests and blood counts.
Topiramate: Blocks voltage-dependent sodium channels, potentiates GABA, inhibits AMPA/kainate glutamate receptors, and blocks L/N-type calcium channels. Dosing: Start at $25\text{ mg/day}$; titrate weekly to target dose of $100\text{ mg/day}$.
Beta-Blockers:
Propranolol ($40\text{--}400\text{ mg/day}$), Metoprolol ($100\text{--}200\text{ mg/day}$), Timolol: Inhibit norepinephrine release via prejunctional beta-receptor blockade and suppress central sensitization.
Triptans (Short-Term Prevention):
Frovatriptan ($2.5\text{ mg}$ once or twice daily): Indicated for short-term prophylaxis of menstrually associated migraine (MAM), initiated 2 days prior to expected menses and continued for 5 days.
Level B Recommendations (Probably Effective)
Antidepressants: Amitriptyline (TCA, start $10\text{ mg}$ at bedtime, max $100\text{--}300\text{ mg/day}$) and Venlafaxine (SNRI, $75\text{--}150\text{ mg/day}$). Work by enhancing descending antinociceptive pathways and blocking sodium channels.
Beta-Blockers: Atenolol ($50\text{--}200\text{ mg/day}$) and Nadolol ($100\text{--}200\text{ mg/day}$).
Triptans: Short-term perimenstrual dosing with Naratriptan ($1\text{ mg BD}$) or Zolmitriptan ($2.5\text{ mg BD/TD}$).
Level C & Level U Status Summary
| Evidence Level | Representative Medications | Clinical Comments |
| Level C (Possibly Effective) | Lisinopril ($20\text{ mg/day}$), Candesartan ($16\text{ mg/day}$), Nebivolol, Clonidine, Carbamazepine. | Useful secondary options when first-line drugs are contraindicated. |
| Level U (Inadequate / Conflicting Data) | Gabapentin, Fluoxetine, Verapamil, Nimodipine, Bisoprolol. | Evidence is currently insufficient to recommend for or against routine use. |
| Established Ineffective (Level A/B Negative) | Lamotrigine (Level A Negative); Clomipramine (Level B Negative). | Should not be prescribed for episodic migraine prevention. |
Complementary and Procedural Options
Nutraceuticals & Supplements:
Butterbur ($75\text{ mg BD}$), Riboflavin/Vitamin B2 ($400\text{ mg/day}$), Elemental Magnesium ($300\text{ mg BD}$), and Co-enzyme Q10 ($100\text{ mg TDS}$) have demonstrated modest prophylactic benefit.
OnabotulinumtoxinA (Botox):
FDA-approved for Chronic Migraine (defined as $\ge 15$ headache days/month) in patients who have failed at least 3 prophylactic drug trials.
Dosing Protocol: $155\text{ to }195\text{ Units}$ injected intramuscularly ($0.1\text{ mL} / 5\text{ Units}$ per site) across $31\text{ to }39$ specific head and neck sites every 12 weeks.
Non-Pharmacological Modalities:
Cognitive-Behavioral Therapy (CBT), Relaxation Training, Aerobic Exercise, and Biofeedback Therapy (EMG, thermal, or electrodermal feedback coupled with relaxation techniques) provide meaningful benefit without pharmaceutical side effects.
Conclusion
Preventive migraine management combines evidence-based medications, targeted interventions like OnabotulinumtoxinA, and non-pharmacological therapies. Customizing treatment based on patient comorbidities and attack frequency reduces disability and helps prevent progression to chronic migraine.